EICHORPublic-registry trials using Trosunilimab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Trosunilimab appears in 1 registered trial Eichor's radar has found, sponsored by AbbVie, the most recent registered as Phase 2, with a planned enrollment of 2,000. Registered timeline: 2026–2031. The registry holds 2,063 registered studies for Crohn's Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis | AbbVie | Crohn's Disease | PHASE2 | 30 |
| Status | Not Yet Recruiting · planned start 2026-07 |
| Primary completion | 2031-10 |
| Enrollment target | 2,000 participants |
| Design | Randomized · Parallel · Phase 2 · 22 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 30 listed in Australia, Belgium, Germany, Japan |
All fields verbatim from the ClinicalTrials.gov record for NCT07697456.
| First registered study | August 2024 — NCT06548542 (AbbVie) |
| Registered studies matching this name | 2 all-time · 1 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 2,063 registered studies for Crohn's Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Crohn's Disease drugs
← Eichor home · All tracked trials · Crohn's Disease studies · Weekly briefs
